- The FDA has accepted Regeneron's (REGN +3.3%) application to expand the use of its Eylea therapy to treat Macular Edema Following Branch Retinal Vein Occlusion, a common vascular disease among the elderly that is caused by a blockage of one of the small veins that carry blood away from the retina.
- Regeneron's application follows a successful Phase III trial.
- Eylea has already been authorized for other indications, including wet age-related macular edema.
Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog
at Zacks.com (Jan 14, 2015)